AVDL250117P17500
- 2.20
- 0.000.00%
Avadel Pharmaceuticals Newsroom
C-Suite Buy of the Week: Unusual Insider Trading Trends as 2025 Approaches
Several Insiders Invested In Avadel Pharmaceuticals Flagging Positive News
Independent Non-Executive Chairman of the Board of Avadel Pharmaceuticals Picks Up 16% More Stock
Avadel Pharmaceuticals Presents Results From Social Listening Analysis And Survey Of People With Narcolepsy Uncover Real-Life Challenges With Twice-Nightly Oxybate Therapy; Findings Published In 'Brain Sciences' Showed Missed Doses And Potential For...
Avadel Chief Commercial Officer Resigns, Stock Down 14%
UBS Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Cuts Target Price to $22
US Manufacturing Index Rises To 43, Highest Since 2020
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference
H.C. Wainwright Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Cuts Target Price to $25
Express News | Avadel Pharmaceuticals PLC : Piper Sandler Raises Target Price to $24 From $23
Avadel Pharmaceuticals Reports Strong Growth With LUMRYZ
Avadel Pharmaceuticals Plc (AVDL) Q3 2024 Earnings Call Transcript Summary
Avadel Pharmaceuticals Plc (AVDL) Q3 2024 Earnings Call Transcript
Avadel Pharmaceuticals Shares Are Trading Lower. The Company Reported Q3 Financial Results.
Avadel Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Avadel Pharmaceuticals | 8-K: Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Avadel Pharmaceuticals Price Target Maintained With a $22.00/Share by Needham
Express News | Avadel Pharmaceuticals: Generated $50.0 Mln of Net Product Revenue From Sales of Lumryz in Q3 of 2024
Avadel Pharmaceuticals Q3 2024 GAAP EPS $(0.03) Beats $(0.06) Estimate, Sales $50.025M Beat $48.607M Estimate
Avadel Pharmaceuticals 3Q Loss/Shr 3c >AVDL